Purpose: Chromosome 13q14 deletion occurs in a substantial number of chronic lymphocytic leukemia (CLL) patients and it is believed to play a pathogenetic role. The exact mechanisms involved in this lesion have not yet been fully elucidated because of its heterogeneity and the imprecise knowledge of the implicated genes. This study was addressed to further contribute to the molecular definition of this lesion in CLL.
advanced stages whereas others survive for a long time without disease progression (1) . Recently, considerable efforts have been addressed to the identification of genomic aberrations that could explain the pathogenetic mechanisms and the clinical heterogeneity of the disease (2) (3) (4) (5) . Deletions of 13q14, 11q22.3, and 17p13, and trisomy 12 are common in CLL and may play a role in pathogenesis and disease progression (4) . 13q14 deletion occurs in approximately 50% of CLL and is associated with a favorable prognosis when present as the sole abnormality (6) . Notably, 2 microRNA genes, miR-15a and miR-16-1, located at 13q14, have been reported to be downregulated in del(13)(q14) patients (7) and strongly suggest their potential role in the disease. However, the 13q14 deletion is not always accompanied by defects in miR-15a/16-1 expression, suggesting a more complex heterogeneity of the deletion itself (8, 9) .
The recent introduction of microarray technology has improved the possibility of combining genome-wide DNA analyses with transcriptomic profiles, thus allowing the identification of potential candidate tumor genes related to underlying chromosomal alterations. To further elucidate the genomic complexity of the 13q14 deletion in CLL, we applied single-nucleotide polymorphism (SNP)-array technology to a panel of 100 untreated patients with Binet stage A disease including 44 patients with 13q deletion as assessed by fluorescence in situ hybridization (FISH). We then investigated the expression levels of the miR-15a/16 cluster by quantitative real-time PCR (qRT-PCR) and global gene expression profiling in a representative panel of cases (see flow chart in Supplementary Figure S1 ). The integration between genomic and expression data allowed the identification of 2 distinct molecular groups of patients with 13q14 deletions. Our data may have implications for the biology and the prognostic stratification of CLL.
Materials and Methods

Patients
The study included samples from 100 untreated CLL patients in Binet stage A: 60 from a retrospective collaborative Italian study (10) and 40 enrolled in an Italian prospective multicenter study (GISL O-CLL1). Eligibility required a diagnosis of a typical CLL phenotype: CD5/ CD19 þ and CD23 þ , weak surface immunoglobulin (sIg), and the monotypical expression of k or l light chains by neoplastic cells. Patients were selected to provide a good numerical representation of cytogenetic lesions, as assessed by FISH, and IgVH mutation status. All the patients gave their informed consent in accordance with our institutional guidelines.
Sample preparation, immunophenotype, and prognostic markers Peripheral blood mononuclear cells were isolated by Ficoll-Hypaque gradient centrifugation (Seromed), and CD38 and ZAP-70 expression were determined by flow cytometry (11) . IgVH gene usage and mutational status were established as previously described (12) , with a 2% cutoff value being used to define mutated and unmutated patients. For the microarray analyses, the CLL cells were enriched by negative selection when less than 90% (11) .
Fluorescence in situ hybridization
The most common genomic aberrations, del(17)(p13), del(11)(q23), del(6)(q23), del(13)(q14), and trisomy 12, were investigated by interphase FISH hybridization. All of the probes are commercially available (Vysis; ref. 13 ).
High-density SNP arrays and data analysis
Total genomic DNA (250 ng) were processed in accordance with the manufacturer's protocol (Affymetrix), hybridized using Affymetrix GeneChip Human Mapping 250K NspI microarrays, and subsequently scanned using a GeneChip Scanner 3000 7G. The images were acquired using the Affymetrix GeneChip Operating System (GCOS 1.4). The accuracy of the SNP array data were confirmed by the mean and median call rates of 95.75% and 96.12% (the quality control specification for 250K arrays is a call rate greater than 93%), respectively.
The entire procedure for the copy number (CN) estimation has been fully described previously (14) . Briefly, the raw data relating to the individual SNPs were extracted from CEL files and converted into signal intensities using GTYPE 4.1 and Affymetrix Copy Number Analysis Tool (CNAT 4.0.1) software. Each sample was compared with a set of 48 normal Caucasian HapMap references available on the Affymetrix web site (http://www.affymetrix.com/ support/technical/sample_data/500k_data.affx) and the genomic smoothing window of the Hidden Markov Model algorithm was set at 0. After preprocessing, piecewise constant estimates of the underlying local DNA CN alterations were calculated using the DNAcopy Bioconductor package, which looks for optimal breakpoints on the basis of circular binary segmentation (15) , and the median values of the estimated profiles were scaled back to a nominal multiplicity of 2. After scaling, we determined all the clusters appearing on the frequency distribution (histogram) of the SNP values for all the SNP probes using the k-means algorithm on the cumulative profile of all of the array data. The transition from one cluster to the other, namely the threshold from one CN to another, was then estimated as the meeting point of 2 Gaussian curves and approximating the distributions of mean m and variance s 2 of the 2 neighboring clusters of SNPs identified in the final clustering. Thus, the thresholds result as follows: inferred CNs of more than 2.1 and 2.5 corresponded to gain and amplification, whereas CNs of less than 1.9 and 1.34 corresponded to loss and biallelic deletion. After segmentation, the SNP dataset was compressed to 1346 probes by eliminating redundant probes to better balance less represented regions with those showing a large number of probes, as previously described (14) . A probe was defined as redundant when it showed CN values identical to those of the most
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contiguous upstream probe in all samples. Then a nonnegative matrix factorization (NMF) procedure adapted to R from the original MATLAB package (16) was used to evaluate the meaningful clusters across the whole dataset. For each factor level from 2 to10, NMF was repeated 100 times to build a consensus matrix, and the samples were assigned to clusters on the basis of the consensus results.
Sequence copy number determination by quantitative real-time PCR Real-time PCR was performed according to a published protocol (17) using the ABI Prism 7900 sequence detection system. Singleplex amplification reactions were carried out in triplicate using 40 ng of template DNA, 1X TaqMan Universal Master Mix, no AmpErase UNG, and a 1X Primer-Probe Mix (Applied Biosystems) containing sequence-specific primers and a fluorogenic probe. The TaqMan RNase P Detection Reagents kit and a Custom TaqMan Gene Expression Assay (forward primer: 5 0 -GCAATGTCAGCAGTGCCTTAG-3 0 ; reverse primer:
0 ) were used to amplify the ribonuclease P RNA component H1 gene mapped within 14q11.2 (present in 2 copies in all of the subjects and thus used as an internal standard) and the miR-15a/ 16-1 cluster. The comparative DCt method was used for quantification purposes. DNA samples from 10 control individuals with 2 copies of the commonly deleted region were selected for PCR calibration. The estimated haploid gene CN was given by the formula 2
ÀDDCt , and the pre- Quantification of specific gene expression by Q-RT-PCR Q-RT-PCR of specific genes (TPT1, WBP4, PEA15, and LGALS1) and mature miRNAs (hsa-miR-15a and hsa-miR-16) was performed using commercial TaqMan assays (Applied Biosystems) as previously described (19) . The relative gene and miRNA expression levels were calculated using the 2
ÀDCt method (Applied Biosystems User Bullettin No. 2) as previously described (19) . Pearson's correlation coefficient was calculated to test correlation between gene expression and Q-RT-PCR data.
Gene expression profiling Twenty-two CLL samples with 13q deletion included in the retrospective database underwent gene expression profiling (GEP) analysis. Total RNA was extracted using the TRIZOL reagent (Invitrogen) and purified using the RNeasy total RNA Isolation Kit (Qiagen). The biotinlabeled complementary RNA was prepared and hybridized with GeneChip Human Genome U133A Arrays (Affymetrix Inc.), which were scanned (GeneChip Scanner 3000 7G; Affymetrix Inc.) in accordance with the manufacturer's protocols. The probe data were converted to expression values using the Bioconductor function for the robust multiarray average procedure, as described previously (20) . Supervised analysis was made using Significant Analysis of Microarrays software, version 3.0.2 (http://www-stat.stanford.edu/$tibs/SAM/index. html/; ref. 21 ). The cutoff point for significance at a median false discovery rate (FDR) less than 5% (i.e., q < 0.05) was determined by tuning the D parameter on the FDR and controlling the q-value of the selected probes. dChip software (22) was used to represent the selected probe lists; NetAffx (https://www.affymetrix.com/analysis/netaffx/) was used for the functional annotation study of the list. The genotyping and gene expression data are available at NCBI's Gene Expression Omnibus through GEO Series Accession no. GSE16746.
Statistical analysis
The data were statistically analyzed using conventional procedures in R software (Kruskal-Wallis tests, Kendall's t correlations, Fisher's exact tests, and q-value calculations).
Results
Molecular characteristics of the CLL patients
The main characteristics of the 100 CLL patients included in the study are reported in Supplementary Tables S1 and  S2 . Based on FISH analyses, 44 cases carried the 13q14 deletion: 34 as the sole abnormality, and the remaining showed 11q22.3 (6 patients), 17p13.1 (2 patients), 11q22.3 and 17p13.1 deletions (1 patient), or 6q23 deletion (1 patient). Biallelic 13q14 deletions were identified in 11 cases, 5 of which (CS3, CZ42, GE110, CS0100 and LD0062) showed the presence of subclones characterized by the biallelic deletion (ranging from 68% to 83.5%). Trisomy 12 was present in 21 patients as a sole abnormality. Overall, the 11q22.3, 17p13.1, and 6q23 deletions were present in 15, 7, and 2 patients, respectively. Fifty-five cases had unmutated IgVH genes; ZAP-70 and CD38 were expressed in 42 and 46 cases, respectively. 13q deletion was present in 25 of 45 (55.5%) patients with mutated IgVH genes, 15 of 42 (35.7%) of the ZAP-70 positive patients, and 15 of 46 (32.6%) of the CD38 positive patients.
SNP array data were concordant with FISH results (Supplementary Tables S2 and S3 ). In addition, SNP arrays detected short deletions involving the second 13q allele in 3 del(13)(q14) patients (TS12, VB0013, and PS0044); deletions were, respectively, 467, 468, and 291-kb long and located centromerically to the LSI D13S25 FISH probe ( Fig. 1A and B) . Furthermore, SNP arrays revealed a 6q deletion of approximately 39 Mb in length and located upstream of the LSI MYB FISH probe in a single patients (CZ47; data not shown). These aberrations were confirmed by specific FISH probes in all cases (data not shown).
Characterization of the 13q deletion by SNP arrays
The SNP arrays showed that the 13q deletions varied considerably in size, ranging from a minimum of 291 kb (PS0044) to a maximum of 56 Mb (CZ36; Fig. 1A and B). The status of the miR-15a/16-1 cluster was investigated further using a custom Q-RT-PCR assay on DNA from 32 patients: 10 with biallelic deletions, 10 with monoallelic deletions, and 12 normal at 13q14 based on SNP array data. As shown in Figure 2A and B and Supplementary Table S4, the estimated CN obtained with this approach were concordant with the SNP array data (P < 0.0001) with 3 exceptions: 2 patients (CS3 and GE110) classified as CN ¼ 1 by RT-PCR and CN ¼ 0 by SNP array, who showed 2 distinct cell populations by FISH characterized by either mono-or biallelic losses, and 1 patient (RC21) classified as normal by RT-PCR and CN ¼ 1 by SNP array who showed a monoallelic loss in a fraction of interphase nuclei (61%; Fig. 2A ). These findings suggest that clonal heterogeneity may account for the discrepancies between the real-time PCR and SNP array data.
Furthermore, we compared miR-15a and miR-16 expressions in 78 of 100 cases including 11 with biallelic deletions, 28 with monoallelic deletions and 39 normal cases based on SNP array CN values. Cases with biallelic deletions had a miRNA expression significantly lower than cases retaining 1 or 2 copies (P < 0.0001 for miR15a, P ¼ 0.0001 for miR-16) whereas no statistically significant differences in miRNA expression levels could be observed between normal cases and those retaining a single copy of the cluster ( Fig. 2B and C ; Supplementary  Table S5) .
Finally, SNP array documented a loss of the RB1 gene in 28 of 44 cases with 13q14 deletion (63.6%). Two samples (CS0100 and TS12) showed a biallelic loss of the RB1 locus, which was associated with a homozygous deletion of the 13q14 FISH probe (case CS0100) or was the result of a small deletion involving the RB1 locus on the second allele (case TS12; Fig. 1B ). All these findings were validated by FISH using the RB1 specific clone RP11-305D15 (data not shown). Identification of 2 genetically distinct patient subgroups with del (13)(q14) To identify the most significant natural grouping of genome profiles in our panel, we used the NMF algorithm. This analysis led to the identification of 4 major groups (correlation coefficient ¼ 0.95) characterized by 13q deletion (groups I and II, 27 and 13 cases, respectively) and by trisomy 12 (group III, 21 cases), whereas no specific alteration could be associated with group IV (39 cases; Fig. 3 ; Table 1 ). Patients from groups I and II differed in the deletion size and for the occurrence of mono-or biallelic deletions: group I included samples with relatively smaller losses, 10 of which showed biallelic deletions, whereas group II included samples with larger losses, all but one (GE110) showing monoallelic deletions. The presence of 4 samples with 13q14 deletions in group IV was in all likelihood related to the fact that the inferred CN values (ranging from 1.74 to 1.85) were very close to the threshold (1.9) between monoallelic deletion and the retention of 2 copies. These "marginal" CN data are consistent with clonal heterogeneity and are in accordance with the small percentage of interphase nuclei detected by FISH showing 13q14 deletion (no more than 21% in all cases), which may affect the clustering analysis. RB1 deletion occurred in 14 of 27 cases in group I (52%), 12 of 13 in group II (92%), and 2 of 4 in group IV. Only 10 of the 44 patients with del(13)(q14) carried additional known genetic lesions, namely 11q22.3 (6 patients), 17p13.1 (2 patients), 11q22.3 plus 17p13.1 (1 patient), 6q23 deletions (1 patient); however, no correlation was found with the 2 specific subgroups I and II. Finally, there was no significant association between cases within NMF groups I and II and CD38 or ZAP-70 expression or IgVH mutational status (data not shown).
Gene expression patterns associated with distinct groups of patients with 13q deletion
Fifteen cases from group I and 7 from group II, for whom RNA material was available, were profiled on GeneChip HG-U133A arrays. To verify whether the 2 groups could be divided on the basis of the differences of their expression profiles, we made a conventional unsupervised analysis using hierarchical agglomerative clustering at different levels on (i) all of the probes in the array; (ii) all of the probes mapped to the chromosome 13; or (iii) all of the probes within the 13q14 region. Notably, a significant grouping (i.e., group I and group II patients in 2 separate branches) was only detected when the 89 probes (65 genes) mapped on the 13q14 region were used (P < 0.0001; Fig. 4A ). This finding indicates that, albeit differences exist between the 2 groups, these are not sufficient to drive the clustering when the global transcriptional profiling was considered (i.e., the whole matrix). Thus, we carried out a supervised analysis to characterize the specific transcriptional profiles distinguishing NMF groups I and II. We identified 76 differentially expressed probe sets, specific to 63 well-characterized genes (Fig. 4B) , 10 of which were downregulated and 53 upregulated in group II compared with group I. Six of the 10 downregulated genes mapped to 13q13-q14 and exhibited a monoallelic deletion in most or all cases within group II [3 of 7 (43%) for FOXO1; 4 of 7 (57%) for EXOSC1 and WBP4; 6 of 7 (86%) for TPT1 and NUFIP1; 7 of 7 (100%) for ESD) compared with cases in group I (1 of 15 (6.7%) for EXOSC1, TPT1, ESD, FOXO1, and NUFIP1; 2 of 15 (13.3%) for WBP4]. The whole list of differentially expressed genes is reported in Table 2 .
We selected 2 downregulated (TPT1 and WBP4) and 2 upregulated (PEA15 and LGALS1) genes in group II versus group I for Q-RT-PCR validation of the microarray data. The Q-RT-PCR analyses were made in a subset of 20 of 22 patients for whom RNA material was available (14 belonging to group I, 6 to group II). The correspondence between the microarray and Q-RT-PCR data were evaluated by assessing the correlation coefficients of the expression levels determined by the 2 analyses: the coefficients were 0.71 for TPT1, 0.79 for WBP4, 0.60 for PEA15, and 0.78 for LGALS1 probe, thus indicating a very good concordance for all of the tested genes ( Supplementary Fig. S2 ).
Discussion
This study focused on the molecular characterization of the 13q14 deletion based on SNP arrays and gene expression profiling analyses. Several aspects distinguish this from previous reports (9, 23) including a homogeneous cohort of untreated early-stage patients (Binet A), the use of highly purified CLL samples and a higher-resolution SNP array (250K NspI), the application of stringent statistics to define the genetic groups, and the integration of genomic and gene expression data in a significant number of cases. The main findings relate to the description of the topography of 13q14 deletions, the reassessment of the fate of miR-15a/16-1 cluster in relation to the genomic losses, and, perhaps more importantly, the definition of 2 major genomic groups of patients with 13q14 deletions also characterized by distinct transcriptional patterns. Table 2 . Table 2 . (Continued on the following page) Table 2 . The natural grouping of genome profiles by SNP array analysis showed that the complex scenario of CN alterations affecting CLL is mainly driven by the presence of the 13q14 deletion and trisomy 12. Our SNP array approach extends previous limited evidence showing that del(13) (q14) patients are characterized by differently sized deletions. Ouillette et al. (9) documented a significant correlation between a wider deletion encompassing the RB1 gene and a higher Rai clinical stage at diagnosis or in previously treated patients. In preliminary observations on our cohort of Binet stage A patients, we did not find any significant differences in the time to treatment between the patients with shorter/biallelic (group I) or wider/monoallelic losses (group II; data not shown), although this finding awaits confirmation by ongoing prospective studies.
Our data support the notion that loss of the miR-15a/ 16-1 locus occurs in virtually all the CLL cases with del(13) (q14); in fact, among 44 cases with 13q deletion in our study, both copies of miRNA cluster were retained in only 2 patients with a monoallelic 13q14 deletion. Furthermore, we found that reduced miR-15a and miR-16 expression levels in patients with del(13)(q14) significantly correlated only with the presence of a biallelic loss, which is in agreement with some recent data (8, 9) but not with the older findings (7). Overall, these findings suggest a need to redefine the pathogenetic role of miR-15a and miR-16-1 in the context of the molecular subtypes of 13q14-deleted patients.
The availability and integration of GEP data allowed a more comprehensive overview of the genetic complexity of the 13q14 deletion. Indeed, this approach led to the determination of distinct transcriptional signatures associated with different groups of 13q14-deleted patients (short/biallelic versus long/monoallelic lesion) identified by the NMF algorithm. In particular, a significant gene dosage effect has been observed involving the downregulation of genes in group II (long/monoallelic deletion), 6 of which localized within the 13q14 region. Among the downregulated genes, we should note TPT1/TCTP (translationally controlled tumor protein) encoding for a highly conserved multifunctional protein acting as a prosurvival and growth stimulating factor (24) , which inhibits BAXinduced apoptosis (25) .
Most of the upregulated genes in group II are involved in cell motility and adhesion, regulation of cell proliferation, tumor cell migration, metastasis, angiogenesis, and apoptosis, and some of these may contribute to lymphomagenesis. This is the case of the autocrine motility factor (AMF)/ glucose phosphate isomerase (GPI) gene, which is upregulated in several human cancers and encodes for a housekeeping cytosolic enzyme involved in both glycolysis and gluconeogenesis (26) . The basigin gene (BSG) encodes a cell surface glycoprotein of the Ig superfamily expressed at the surface of tumor cells metastasizing in bone marrow (27) and is believed to induce matrix metalloproteinases production (28) . The Galectin-1 (alias LGALS1) gene encoding a 14-kDa lectin, is overexpressed in numerous tumors including lymphomas (29) and CLL, and is implicated in abnormal mechanisms of cell adhesion, induction of apoptosis, and tumor angiogenesis (30, 31) . PAK2 belongs to the p21-activated kinase family, which are well-known regulators of cytoskeletal remodelling, cell motility, proliferation, and apoptosis (32) . Finally, 2 other upregulated genes, b-parvin (PARVB) and vimentin (VIM), have been reported to play a critical role in transducing signals from integrins to the actin cytoskeleton and intracellular signaling proteins (33) . Low levels of PARVB correlate with low adhesion to collagen (34) , whereas increased levels reduce the activating phosphorylation of AKT (35) , causing propensity to apoptosis. Upregulation of VIM is thought to provide a selective advantage to tumor cells following signaling cues from mesenchymal and epithelial extracellular matrixes (36) . Notably, a modulation of genes thought to act as regulators of tumor invasion and integrin-mediated cell motility and adhesion has been recently described in CLL, in particular during disease progression (37, 38) .
In conclusion, our data may represent a valid contribution to the definition of the genomic profile of CLL. In particular, we provide evidence of 2 clearly distinguishable molecular subtypes among CLL patients with 13q14 deletion that may contribute toward the better understanding of the pathogenetic and clinical relevance of this lesion in CLL.
